SCHEMBL10107617

SCHEMBL10107617

CCCCOc1c(NC(=O)OC(C)(C)C)nc(N(C)C)c(C)c1C(=O)Oc1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 7/20 0.39
TDP2 O95551 2/20 0.36
CNR2 P34972 1/20 0.35
IDO1 P14902 1/20 0.34
CYP1A2 P05177 2/20 0.33
CYP2C9 P11712 2/20 0.33
TSHR P16473 2/20 0.33
CYP2C19 P33261 2/20 0.33
CTSK P43235 2/20 0.33
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.33
CYP2D6 P10635 1/20 0.33
HPGD P15428 1/20 0.33
ALOX15 P16050 1/20 0.33
MAPK1 P28482 1/20 0.33
CASP3 P42574 1/20 0.33
RAB9A P51151 1/20 0.33
SENP8 Q96LD8 1/20 0.33
HSD17B10 Q99714 1/20 0.33
SENP7 Q9BQF6 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10107750 0.87 FAAH (0.40) FAAHTDP2CNR2IDO1CYP1A2
SCHEMBL10107728 0.87 FAAH (0.40) FAAHTDP2CNR2IDO1CYP1A2
SCHEMBL14679403 0.84 FAAH (0.38) FAAHCYP1A2CYP2C9TSHRCYP2C19
SCHEMBL10107723 0.84 FAAH (0.40) FAAHTDP2CNR2IDO1CYP1A2
SCHEMBL16015533 0.84 LMNA (0.36) FAAHCYP1A2CYP2C9TSHRCYP2C19
SCHEMBL10107544 0.83 F2 (0.34) FAAHCYP1A2CYP2C9TSHRCYP2C19
SCHEMBL10107486 0.80 LMNA (0.41) FAAHCYP1A2CYP2C9TSHRCYP2C19
SCHEMBL10107487 0.76 MAPT (0.39) FAAHCYP1A2CYP2C9TSHRCYP2C19
SCHEMBL17849870 0.76 FAAH (0.39) FAAHTDP2CNR2RAB9A
SCHEMBL16015534 0.75 LMNA (0.36) FAAHCYP1A2CYP2C9TSHRCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8828988-B2 8-AZA tetracycline compounds TETRAPHASE PHARMACEUTICALS, INC. (US) 2014-09-09 US disclosed
US-20120108569-A1 8-AZA Tetracycline Compounds TETRAPHASE PHARMACEUTICALS, INC. 2012-05-03 US disclosed
WO-2010129055-A1 8-AZA TETRACYCLINE COMPOUNDS TETRAPHASE PHARMACEUTICALS, INC. (US) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108569-A1 8-AZA Tetracycline Compounds TET1, TET3, HDAC8 FAAH 4675/4885TDP2 981/4885CNR2 4842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.